NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - Nuvation Bio Inc. is under investigation by the Schall Law Firm for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Financial Performance - Nuvation reported its Q4 and full year 2025 financial results on March 2, 2026, revealing that a significant portion of early patient starts for its IBTROZI oncology therapy were in later-line treatment settings [2]. - The company disclosed that 75% of treatment discontinuations were from these later-line patient populations, which contributed to a gap between the number of patients starting IBTROZI and its net product revenue growth [2]. - Following this announcement, shares of Nuvation fell by 25.3% the next day [2]. Legal Context - The Schall Law Firm is encouraging shareholders who suffered losses to participate in the investigation and discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].